ProfileGDS5678 / 1454007_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 52% 52% 52% 52% 51% 50% 52% 52% 53% 52% 53% 52% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2852251
GSM967853U87-EV human glioblastoma xenograft - Control 23.2768252
GSM967854U87-EV human glioblastoma xenograft - Control 33.277252
GSM967855U87-EV human glioblastoma xenograft - Control 43.2169652
GSM967856U87-EV human glioblastoma xenograft - Control 53.2137352
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3301951
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2911450
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2660952
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2601352
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2745653
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2594752
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2613353
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2726152
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2629852